Home » Topics » Disease categories and therapies » Urology

Urology
RSS

Takeda describes tachykinin receptor antagonists

July 10, 2009

Vasopressin V1b receptor ligands under development at Abbott

July 3, 2009

Vantia reports results from phase IIa clinical trial of VA-106483 in nocturia

July 1, 2009

AEterna Zentaris presents update on phase III study 041 of cetrorelix pamoate in BPH

June 19, 2009

FibroGen starts enrollment in phase II FG-3019 study in diabetic kidney disease

June 17, 2009

Genzyme receives European approval of Renvela for chronic kidney disease

June 15, 2009

AEterna opens extended study for cetrorelix in benign prostatic hyperplasia

June 15, 2009

CHMP adopts positive opinion for Otsuka's Samsca in hyponatremia

June 12, 2009

Keryx reports results from phase II study of Zerenex for hyperphosphatemia in ESRD

June 10, 2009

NOXXON initiates dosing of healthy volunteers in phase I clinical trial of NOX-E36

June 10, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...